Comprehensive treatment of severe diseases, accompanied by liver (acute and chronic), renal (acute and chronic) and hepatic-renal failure syndromes, requires intensification in therapeutic measures involving the introduction of efferent therapy (plasmapheresis, hemosorption, plasma sorption, etc.). Direct damage of the liver parenchyma, its functional load under the conditions of these syndromes is due to the depth of cytolytic processes, characterized by an increase in the level of indicator enzymes: alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), and others.